SRF delivered results which were surpassed our estimates. While Revenue grew by 7% YoY, EBITDA and Adjusted PAT grew by rates of 7% and 11% from a very strong base quarter in Q4FY25.The chemicals business continued to exhibit strong growth owing to higher HFC pricing and placement of higher volumes in domestic and export markets. SRF delivered on the guidance of a robust Q4FY26 performance on the back of conversion of pent up and deferred orders. Specialty Chemicals Business clocked in steady revenue growth of 16% for FY26 with margins coming in at healthy 29%. SRF is undertaking significant capex into...